Hologic - HOLX Stock Forecast, Price & News

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last year. There are currently 8 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HOLX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HOLX, but not buy additional shares or sell existing shares.
View HOLX analyst ratings or view top-rated stocks.

15 Wall Street analysts have issued 1-year price objectives for Hologic's stock. Their HOLX share price forecasts range from $70.00 to $95.00. On average, they expect the company's share price to reach $84.08 in the next year. This suggests a possible upside of 6.2% from the stock's current price.
View analysts price targets for HOLX or view top-rated stocks among Wall Street analysts.

Hologic's stock was trading at $74.81 at the beginning of the year. Since then, HOLX shares have increased by 5.9% and is now trading at $79.20.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our HOLX earnings forecast.

Hologic, Inc. (NASDAQ:HOLX) issued its quarterly earnings results on Wednesday, February, 1st. The medical equipment provider reported $1.07 EPS for the quarter, topping analysts' consensus estimates of $0.90 by $0.17. The medical equipment provider earned $1.07 billion during the quarter, compared to analyst estimates of $1.01 billion. Hologic had a net margin of 22.17% and a trailing twelve-month return on equity of 25.12%. The firm's quarterly revenue was down 27.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.17 EPS.
Read the conference call transcript.

ETFs with the largest weight of Hologic (NASDAQ:HOLX) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), VictoryShares THB Mid Cap ESG ETF (MDCP), The Acquirers Fund (ZIG), Gabelli Automation ETF (GAST), SEI Enhanced U.S. Large Cap Quality Factor ETF (SEIQ), VictoryShares Nasdaq Next 50 ETF (QQQN), First Trust Indxx Medical Devices ETF (MDEV) and First Trust Capital Strength ETF (FTCS).

Hologic updated its FY23 earnings guidance on Wednesday, February, 1st. The company provided EPS guidance of $3.55-$3.85 for the period, compared to the consensus estimate of $3.56. The company issued revenue guidance of $3.85-$4.00 billion, compared to the consensus revenue estimate of $3.90 billion.

447 employees have rated Hologic Chief Executive Officer Steve MacMillan on Glassdoor.com. Steve MacMillan has an approval rating of 79% among the company's employees. 81.0% of employees surveyed would recommend working at Hologic to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Hologic investors own include AbbVie (ABBV), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), Walt Disney (DIS), PayPal (PYPL), Advanced Micro Devices (AMD), CVS Health (CVS), Pfizer (PFE) and Abbott Laboratories (ABT).

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

Hologic's stock is owned by a number of retail and institutional investors. Top institutional shareholders include T. Rowe Price Investment Management Inc. (9.48%), Geode Capital Management LLC (2.35%), Macquarie Group Ltd. (2.33%), Victory Capital Management Inc. (2.10%), Victory Capital Management Inc. (2.09%) and Price T Rowe Associates Inc. MD (1.79%). Insiders that own company stock include Benjamin Jordan Cohn, Jan Verstreken, John M Griffin, Karleen Marie Oberton, Kevin R Thornal, Peter J Valenti III, Sally Crawford, Sean S Daugherty, Sean S Daugherty and Stephen P Macmillan.
View institutional ownership trends.

Shares of HOLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HOLX stock can currently be purchased for approximately $79.20.

Hologic (NASDAQ:HOLX) has a market capitalization of $19.53 billion and generates $4.86 billion in revenue each year. The medical equipment provider earns $1.30 billion in net income (profit) each year or $3.92 on an earnings per share basis.

The company employs 6,944 workers across the globe.

Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The official website for the company is www.hologic.com. The medical equipment provider can be reached via phone at (508) 263-2900, via email at michael.watts@hologic.com, or via fax at 781-890-8031.